Skip to main content
. 2018 Sep 21;9(74):33995–34008. doi: 10.18632/oncotarget.26129

Figure 3. RICTOR enhances the malignant phenotype of NSCLC in vitro and in vivo.

Figure 3

(A) (Top) Colony formation assay of 3 RICTOR amplified cell lines (H23, H2009, H1792) and 2 non-amplified cell lines (A549, HCC193) comparing RICTOR knockdown to non-targeting control. Data are graphed as the mean percentage ± percent SD. (Bottom) Anchorage-independent growth assay in soft agar of stably transduced H23 cell line with RICTOR knockdown (A549 serves as positive control). *P < 0.05; n.s. = not significant. (B) Quantification of the cell number counts of shRICTOR cells relative to NTC cells at the indicated time points following doxycycline treatment. Complete cell counts were performed following 4, 8, 12, 16 days of incubation and shown as percentage relative to NTC. (C) Athymic nude mice were inoculated with H1792 or H23 cell lines and were fed either doxycycline (+Doxy, 600mg/kg) or control diet (–Doxy). Tumor volumes were measured twice weekly. Data points are presented as the mean tumor volume ± SEM. Representative images of xenograft tumors from each group before tumor harvesting are shown. *P = 0.01; **P < 0.01. (D) Lysates extracted from H1792 tumor xenografts were subjected to Western blot analysis with the indicated antibodies.